Correlation between plasma TAFI levels and risk of RSA
Table 4 shows the correlations between plasma TAFI levels explored in the binary logistic regression model and the risk of RSA. The total population was divided into three groups according to the normal range of plasma TAFI levels: normal levels of plasma TAFI were defined as 24-35ug/ml, TAFI<24ug/mL, TAFI>35ug/mL. The adjusted covariates for each group were the variables that were statistically significant by logistic regression. Compared with TAFI levels of 24-35ug/ml. In the Anti-TPO positive group, the risk of RSA was significantly increased in those with TAFI <24 (OR, 2.15; 95% CI, 1.221-3.785; P=0.008). This result was also seen in the Anti-TPO negative group and the Anti-TG positive group. In the Anti-TPO negative group, the risk of RSA was increased in those with TAFI <24 (OR, 1.429; 95% CI, 1.032-1.98; P=0.032); in the Anti-TG positive group, the risk of RSA was significantly increased in those with TAFI <24 (OR, 2.215; 95% CI, 1.265-3.878; P=0.005). It is important to note that in the Anti-TPO negative group, the OR for the increased risk of RSA in the TAFI <24 population was smaller than in the two-positive group.
As shown in Fig1, the multivariate adjusted spline regression model showed a linear negative dose response relationship between TAFI and RSA in all subgroups, with P values for nonlinearity all greater than 0.05. Of note, in the two positive subgroups, OR value was approximately less than 1 when TAFI levels were within the normal reference range of 24-35 ug/mL. However, when TAFI levels were below 24 ug/mL, the OR value increased and was higher than that in the two negative subgroups. On the other hand, when TAFI levels were above 35 ug/mL, an increasing TAFI level was found to be associated with a higher risk of RSA, but the trend is not obvious. This trend was not observed in the two negative subgroups.